DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance
- PMID: 15520212
- DOI: 10.1158/0008-5472.CAN-03-3942
DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance
Abstract
DNA polymerase zeta participates in translesional bypass replication. Here we show that reduced expression of the catalytic subunit hREV3 renders human fibroblasts more sensitive to the cytotoxic effect of cisplatin, reduces their sensitivity to the ability of cisplatin exposure to generate drug resistant variants in the surviving population, and reduces the rate of emergence of resistance to cisplatin at the population level. Reduction of REV3 mRNA did not alter the rate of cisplatin adduct removal but did impair both spontaneous and cisplatin-induced extrachromosomal homologous recombination and attenuated bypass replication as reflected by reduced ability to express luciferase from a platinated plasmid. Cisplatin induced a concentration- and time-dependent increase in hREV3 mRNA. The results indicate that, following formation of cisplatin adducts in DNA, REV3 mRNA levels increase, and polymerase zeta functions to promote both cell survival and the generation of drug-resistant variants in the surviving population. We conclude that when cisplatin adducts are present in the DNA, polymerase zeta is an important contributor to cisplatin-induced genomic instability and the subsequent emergence of resistance to this chemotherapeutic agent.
Similar articles
-
DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.Clin Cancer Res. 2006 Jan 15;12(2):563-8. doi: 10.1158/1078-0432.CCR-05-1380. Clin Cancer Res. 2006. PMID: 16428501
-
DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance.Mol Cancer Ther. 2006 May;5(5):1239-47. doi: 10.1158/1535-7163.MCT-05-0491. Mol Cancer Ther. 2006. PMID: 16731756
-
Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin.Mol Pharmacol. 2005 Jun;67(6):1852-60. doi: 10.1124/mol.104.010579. Epub 2005 Mar 9. Mol Pharmacol. 2005. PMID: 15758147
-
DNA polymerase zeta: new insight into eukaryotic mutagenesis and mammalian embryonic development.World J Gastroenterol. 2003 Jun;9(6):1165-9. doi: 10.3748/wjg.v9.i6.1165. World J Gastroenterol. 2003. PMID: 12800216 Free PMC article. Review.
-
DNA polymerase zeta (pol zeta) in higher eukaryotes.Cell Res. 2008 Jan;18(1):174-83. doi: 10.1038/cr.2007.117. Cell Res. 2008. PMID: 18157155 Review.
Cited by
-
Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells.J Virol. 2005 Jul;79(13):8079-89. doi: 10.1128/JVI.79.13.8079-8089.2005. J Virol. 2005. PMID: 15956553 Free PMC article.
-
Developmental delay with hypotrophy associated with homozygous functionally relevant REV3L variant.J Mol Med (Berl). 2021 Mar;99(3):415-423. doi: 10.1007/s00109-020-02033-3. Epub 2021 Jan 20. J Mol Med (Berl). 2021. PMID: 33474647
-
Rad5 template switch pathway of DNA damage tolerance determines synergism between cisplatin and NSC109268 in Saccharomyces cerevisiae.PLoS One. 2013 Oct 10;8(10):e77666. doi: 10.1371/journal.pone.0077666. eCollection 2013. PLoS One. 2013. PMID: 24130896 Free PMC article.
-
Human Pol ζ purified with accessory subunits is active in translesion DNA synthesis and complements Pol η in cisplatin bypass.Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):2954-9. doi: 10.1073/pnas.1324001111. Epub 2014 Jan 21. Proc Natl Acad Sci U S A. 2014. PMID: 24449906 Free PMC article.
-
REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy.Neuro Oncol. 2009 Dec;11(6):790-802. doi: 10.1215/15228517-2009-015. Neuro Oncol. 2009. PMID: 19289490 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous